BLAINTRAVENOUSVIALPriority Review
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTASCINT (capromab pendetide) is a radiolabeled monoclonal antibody targeting prostate-specific membrane antigen (PSMA) used as a diagnostic imaging agent for prostate cancer detection and staging. Administered intravenously, it localizes to prostate cancer cells and is detected via radioimaging to identify metastatic disease.
LOE Approaching
Product is in late-stage lifecycle with significant competitive pressure (30%), indicating defensive positioning and potential team restructuring or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy
Started Jan 2015
19 enrolled
Prostate Cancer
Career Relevance
Working on PROSTASCINT offers limited growth trajectory but valuable diagnostic oncology and specialty sales experience in a mature, stable product. Career progression will depend on organizational restructuring and competitive defense strategies rather than new indication launches.
Brand Manager
Worked on PROSTASCINT at Biocytogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.